



FOR IMMEDIATE RELEASE

Extension of Prospectus Closing Date and Change of Name to NxGen Pharmaceuticals

SYDNEY, AUSTRALIA – 22nd May 2009 – NuSep (ASX: NSP) wishes to advise that it has agreed to extend the closing date for the prospectus to Friday 29 May following on from requests from NuSep shareholders.

Please note that NuSep will change its name to NxGen Pharmaceuticals on 26 June and will re list under the ASX code of NXG.

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global bioseparations market. The company has offices in both Sydney, Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

-  **Gels** – NuSep manufactures and sells precast gels including the innovative iGels, with a 2 year shelf life.
-  **Separation Instruments** – NuSep has developed two unique biological separation instruments. The first instrument released in February 2008 can separate biological samples into 8 fractions for use in the proteomic market. The second instrument separates sperm for fertility treatments such as IVF and is presently undergoing clinical trials.
-  **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

Contact:
Prakash Patel
Chief Financial Officer & Company Secretary
+61 2 8977 9000
prakash.patel@nusep.com

NuSep Ltd
22 Rodborough Rd
Frenchs Forest NSW 2086

Postal Address
P.O. Box 6126
Frenchs Forest NSW 2086

Contact Details
Telephone +61 2 8977 9000
Facsimile +61 2 8977 9099

Email info@nusep.com
Web www.nusep.com
ABN 33 120 047 556

About NxGen

NxGen's main products are:

Sexual Health Products

NxGen has developed a range of products that address erectile dysfunction, premature ejaculation and female sexual dysfunction.

Erectile Dysfunction (ED)

NxGen's ED nasal spray is now a market leader in the Australian US\$50 million market. This product is supplied by ACP directly to the patient and competes directly with Pfizer's Viagra, Eli Lilly's Cialis and Bayer's Levitra. NxGen receives a product licensing fee on these sales from ACP. The Australian ED market is approximately 1/20th of the US market in terms of market size.

Premature Ejaculation (PE)

According to a global study of sexual attitudes and behaviours¹, 14% of the male population suffers from PE compared with 10% who suffer from ED. This suggests that the market for PE treatment may be significantly larger than the US\$3.8 billion ED market. Treatment options are limited and there is no licensed competitive product that addresses this market need.

Female Sexual Dysfunction (FSD)

Female sexual dysfunction affects as many as four in every 10 women at some point in their lives. NxGen has developed a gel formulation to address FSD in the Australian market. While it is too early to project future sales of this product the initial uptake has been encouraging.

Compound Pharmacy Products

ACP, NxGen's strategic pharmacy partner fills and ships on average over 1,400 products a day across Australia. These are all products developed by NxGen. Each of these is an individual prescription issued by an Australian based doctor. Based on this, NxGen has developed a unique ability to license and develop new pharmaceutical products.

Naltrexone – Addiction Implants

NxGen has developed a time release naltrexone implant that is effective against alcoholism, nicotine, gambling and opiate addictions. Clinical trials will shortly commence for NxGen's alcohol, nicotine and opiate substance abuse products. Future projects include implants for methamphetamine (ice) and cocaine addiction.

¹ Sexual behaviour and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviours. Urology 2004 64: 991-997.